Carregant...
Resistance to Antiestrogen Arzoxifene Is Mediated by Overexpression of Cyclin D1
Resistance to tamoxifen treatment occurs in approximately 50% of the estrogen receptor (ER)α-positive breast cancer patients. Resistant patients would benefit from treatment with other available antiestrogens. Arzoxifene is an effective growth inhibitor of ERα-positive breast cancer cells, including...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
The Endocrine Society
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2737554/ https://ncbi.nlm.nih.gov/pubmed/19477949 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/me.2008-0268 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|